Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

Abstract Background The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the c...

Full description

Bibliographic Details
Main Authors: Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou, Tien-Hsing Chen
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cardiovascular Diabetology
Subjects:
Linagliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Type 2 diabetes mellitus
Acute coronary syndrome
Acute ischemic stroke
Cardiovascular outcome
Online Access:http://link.springer.com/article/10.1186/s12933-017-0655-y

Internet

http://link.springer.com/article/10.1186/s12933-017-0655-y

Similar Items